In MDD, we found some evidence to support that up-regulation of the IL-6R may be risk increasing conditioned on CRP and BMI, supporting preliminary data that blockade of IL-6R by agents such as tocilizumab may decrease depressive symptoms (45). The gene discussed is IL6R; the disease is major depressive disorder.